Anbio Biotechnology
NNNNHealthcareNASDAQMedical Instruments & Supplies · Last scanned Jun 2, 2026
Scan Results
Daily timeframePart of the healthcare sector, Anbio Biotechnology (NNNN) is listed under Medical Instruments & Supplies. The company carries a $1.32B market cap, placing it firmly in the small-cap category. The company offers lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification, SHA dry chemistry, chemiluminescence immunoassay, and real-time polymerase chain reaction solutions; and SARS-CoV-2 and SARS-CoV-2/Flu A/Flu B antigen rapid test kits.
Market Cap
$1.32B
Beta
—
P/E (TTM)
201.13
P/E (Fwd)
—
EPS (TTM)
$0.15
EPS (Fwd)
—
ROE
27.1%
ROA
14.7%
Cash
$11.9M
Total Debt
$0
Free CF
-$9.6M
52W Change
268.0%
Annual Financials
Cash vs Debt
Anbio Biotechnology reports $11.9M in cash and $0 in total debt. The company is burning cash, with free cash flow at -$9.6M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at 27.1%, which is strong for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Return on assets of 14.7% further supports the picture of efficient asset utilization. Revenue has been uneven over recent years, ranging from $23.5M to $8.6M.
The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. The elevated P/E ratio means the stock is priced for significant future growth. If earnings disappoint, the price correction could be sharp. No single metric tells the full story. Reviewing NNNN's risk profile alongside its fundamentals and technical indicators provides a more complete picture.